Endocrine Abstracts

Introduction: Pasireotide (PAS) is an effective treatment for Cushing’s disease (CD) but its use is burdened by the high incidence of diabetes mellitus (DM). We aimed to evaluate the effect of a single subcutaneous injection of PAS on glucose metabolism in CD patients, to identify factors predicting rapid deterioration of glycaemic control.Methods: 14 patients [(f/m=12/2, mean age 43±11.3 years, follow-up 17 months (2-63)] with CD treated with ...

Introduction: Since DI was reported to be associated to increase mortality, the aim of this study is to evaluate the presence of autonomic dysfunction (AD) in patients with DI.Methods: We enrolled 12 patients (six females) with central idiopathic DI and 12 controls, matched for age, sex and common cardiovascular risk factors, who were evaluated using the tilt, lying-to-standing, hand grip, deep breath, Valsalva maneuver and Stroop tests.<p class="abs...

Introduction: The diagnosis of Cushing’s syndrome (CS) might be challenging especially in ACTH-dependent CS when it comes to detect the origin of ACTH secretion.Materials and methods: We retrospectively recorded data about 170 patients with ACTH-dependent CS (149 CD, 21 EAS) referring to two Endocrinology Units. We focused especially on the performance of 3 dynamic tests: the dexamethasone 8 mg overnight challenging (HDDST), the CRH and the desmopre...

Introduction: Transsphenoidal surgery (TSS) is the first-choice treatment in Cushing’s disease (CD). When performed by experienced neurosurgeon, post-operative remission can be achieved in 70–80% of cases; however, recurrences during follow-up are quite frequent, involving around 20–30% of patients initially in remission. Early detection of relapses is crucial to avoid cortisol-related comorbidities. The aim of the study was to find reliable predictors of rec...

: Patients with Cushing’s disease (CD) have increased cardiovascular risk due to metabolic alterations caused by glucocorticoids excess. Pasireotide, a multireceptor-targeted somatostatin analogue, is a therapeutic option in CD patients in whom surgery is not curative or not feasible. Pasireotide has been shown to be effective in controlling hypercortisolism and to improve metabolic features. Recently, the visceral adiposity index (VAI) has been proposed as a marker of vi...

A recent phase III clinical trial has demonstrated that the treatment with the somatostatin analogue pasireotide normalizes cortisol secretion in 15–28% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the effectiveness of 6-months pasireotide treatment on clinical and hormonal profiles in a group of CD patients with mild to moderate disease according with the real-word evidence. Thirty-two patients with CD unsuccessfully treated ...